FDA requests further data for approval of Epigenomics' blood based colorectal cancer screening test
Epigenomics adjusts 2015 outlook after FDA response letter.
Epigenomics has received a response letter from the FDA in relation to its premarket approval (PMA) application for the company's blood-based colorectal cancer (CRC) screening test Epi proColon.
In its letter, the FDA provided guidance and recommendations on how to amend the PMA to make it approvable. The agency requested additional data demonstrating that the blood-based Epi proColon test will increase compliance to CRC screening in the intended use population; i.e., in those patients with a history of noncompliance to recommended CRC screening programs.
The management of Epigenomics is taking immediate steps to address the FDA's requests. This includes a meeting with the FDA in the near term to discuss how to best address the outstanding questions. It is expected that an additional study to demonstrate increased compliance and adherence of patients to blood-based CRC testing will be needed. Details of the study will be determined in dialogue with the FDA.
Epigenomics says it is committed to provide information about the regulatory way forward to its shareholders and to the public in a timely and comprehensive manner.
Together with its strategic commercialization partner Polymedco, Epigenomics will continue to diligently prepare for commercializing Epi proColon in the US.
In the previous ADMIT (Adherence to Minimally Invasive Testing) study, Epigenomics aimed to demonstrate that Epi proColon will increase CRC participation in patients being offered this convenient blood-based test as compared to those being offered a fecal immunochemical test (FIT). While the adherence to Epi proColon was nearly 100%, the participation rate to the FIT-test of 88% by far exceeded the levels seen in many studies. The FDA's request for additional data suggests that the studied population in the ADMIT trial was not fully suitable for Epi proColon.
"While disappointed by the FDA's decision, we will make every effort to address the outstanding questions as soon as possible", said Dr Thomas Taapken, CEO/CFO of Epigenomics AG. "We remain highly committed to providing an innovative and convenient option to those many Americans who do not undergo colorectal cancer screening. Colorectal cancer is still the second-leading cause of cancer death in the US."
Epigenomics has announced that it has adjusted its financial outlook for fiscal year 2015 following the FDA response letter on the company's lead product Epi proColon. Such a decision has a significant impact on the achievement of certain projected financial parameters for 2015.
The company's financial outlook for 2015 changes as follows:
Revenue is projected to exceed last year's figure of EUR 1.5 million, which is significantly less than the projected EUR 3–4 million. In the first 9 months 2015, Epigenomics recorded revenue of EUR 1.3 million* (9M 2014: EUR 1.1 million).
EBIT is now projected at the lower end, or may slightly fall short, of the previous outlook range of EUR -10.0 to -11.0 million. Cash consumption is projected at the upper end of, or may slightly exceed, the previous outlook range of EUR 9.5 to 10.5 million.
*preliminary; final report on first nine months of 2015 will be published on 18 November 2015
Related News
-
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute. -
News New WHO health emergency guidelines expect full transparency from Big Pharma
The WHO are proposing a new set of pandemic guidelines to set out how future global health crises should be handled.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance